Keytruda plus Lenvima demonstrates long-term, durable survival benefit versus sunitinib as first-line treatment for patients with advanced RCC

First-line treatment for patients with advanced RCC

“Keytruda plus Lenvima continues to demonstrate durable clinical benefit as a first-line treatment for patients with advanced renal cell carcinoma, as shown by the clinically meaningful improvement in overall survival sustained with four years of follow up,” said Dr. Thomas Hutson, DO, Pharm.D., FACP, Director of the Urologic Oncology Program and Co-chair of the Urologic Cancer Research and Treatment Center, Texas Oncology at Baylor Sammons Cancer Center. “Furthermore, these data also showed clinically meaningful improvements in median PFS and ORR compared to sunitinib. These findings reinforce the important role of Keytruda plus Lenvima as a first-line standard of care treatment option for patients with advanced renal cell carcinoma.”